Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482835 | 1.00 | RAB9A (0.43) | RAB9AHPGDL3MBTL1GAAPOLB | |
| SCHEMBL2482831 | 1.00 | RAB9A (0.43) | RAB9AHPGDL3MBTL1GAAPOLB | |
| SCHEMBL17074314 | 0.94 | SLC6A3 (0.45) | RAB9AHPGDL3MBTL1GAAPOLB | |
| SCHEMBL536802 | 0.81 | HPGD (0.39) | RAB9AHPGDL3MBTL1GAAPOLB | |
| SCHEMBL18281723 | 0.80 | HPGD (0.40) | RAB9AHPGDL3MBTL1GAAPOLB | |
| SCHEMBL17870819 | 0.80 | HPGD (0.40) | RAB9AHPGDL3MBTL1GAAPOLB | |
| SCHEMBL11851506 | 0.78 | MEN1 (0.41) | RAB9AHPGDL3MBTL1GAAPOLB | |
| Acetic Acid SCHEMBL7279012 | 0.78 | RAB9A (0.39) | RAB9AHPGDL3MBTL1GAAPOLB | |
| SCHEMBL4411156 | 0.77 | SMN1; SMN2 (0.42) | RAB9AHPGDL3MBTL1GAAPOLB | |
| SCHEMBL4357915 | 0.77 | KMT2A (0.40) | RAB9AHPGDL3MBTL1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815212-B2 | Cytotoxin compounds and methods of isolation | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-10-27 | — | — | US | disclosed |
| CN-106536489-B | Retinoid-related orphan receptor gamma modulators and uses thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-3148975-B1 | PIPERAZINE DERIVATIVES AS ROR-GAMMA MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| EP-3148975-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015092575-A1 | GENE CLUSTER FOR BIOSYNTHESIS OF PAMAMYCIN | BASF SE (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20140194495-A1 | CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION | THE UAB RESEARCH FOUNDATION (US) | 2014-07-10 | — | — | US | disclosed |
| US-8669376-B2 | Cytotoxin compounds and methods of isolation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2013337-B1 | A GROUP OF ESTERASES FOR THE ENANTIOSELECTIVE PRODUCTION OF FINE AND SPECIALITY CHEMICALS | BRAIN BIOTECHNOLOGY RES & INFORMATION NETWORK AG (DE) | 2013-03-27 | — | — | EP | disclosed |
| EP-2385109-A2 | A group of esterases for the enantioselective production of fine and speciality chemicals | B.R.A.I.N. Biotechnology Research And Information Network AG (DE) | 2011-11-09 | — | — | EP | disclosed |
| EP-2377930-A1 | A group of esterases for the enantioselective production of fine and speciality chemicals | B.R.A.I.N. Biotechnology Research And Information Network AG (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20090311745-A1 | GROUP OF ESTERASES FOR THE ENANTIOSELECTIVE PRODUCTION OF FINE AND SPECIALITY CHEMICALS | B.R.A.I.N AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090192215-A1 | Cytotoxin Compounds and Methods of Isolation | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1934196-A2 | CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION | University of South Florida (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007035734-A2 | CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197978-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | RAB9A 1240/4885HPGD 2450/4885L3MBTL1 3289/4885 |
| US-20140194495-A1 | CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION | XPA, ANXA5, ST14 | RAB9A 1710/4885HPGD 3481/4885L3MBTL1 1728/4885 |
| US-20090192215-A1 | Cytotoxin Compounds and Methods of Isolation | XPA, ANXA5, ST14 | RAB9A 1710/4885HPGD 3481/4885L3MBTL1 1728/4885 |
| US-10815212-B2 | Cytotoxin compounds and methods of isolation | XPA, ANXA5, ST14 | RAB9A 1710/4885HPGD 3481/4885L3MBTL1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.